JPRN-UMIN000008413已完成未知
Phase II study of combination chemotherapy of gemcitabine, TS-1 and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. - combination chemotherapy of GEM,TS-1 and NAM for advanced pancreatic cancer.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Pulmonary fibrosis or interstitial pneumonia detectable on chest X-ray 2)Active infection 3)Uncontrollable heart disease and myocardial infarction within 6 months 4)Uncontrollable DM 5)Pregnant or lactation women, or women with known or suspected pregnancy 6)History of severe drug allergy 7)Active synchronous or metachronous malignancy
研究者
相似试验
已完成
不适用
Phase II study of combination chemotherapy of gemcitabine, TS-1 and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.nresectable advanced pancreatic cancerJPRN-UMIN000006161Jikei University school of Medicine30
已完成
不适用
Phase II study of induction chemotherapy with gemcitabine and S-1 followed by chemoradiotherapy with S-1 in patients with locally advanced pancreatic cancerlocally advanced pancreatic cancerJPRN-UMIN000006332Chiba Cancer Center30
已完成
2 期
A phase 2 study of combination therapy with gemcitabine and candesartan in patients with advanced or recurrent pancreatic cancerpancreatic cancerJPRN-UMIN000005580niversity of Tokyo, Department of Gastroenterology33
已完成
2 期
A phase 2 study of combination therapy with gemcitabine S-1 and leucovorin in patients with pancreatic cancerPancreatic cancerJPRN-UMIN000010720The University of Tokyo Hospital49
已完成
不适用
Exploratory trial of a combination therapy of Gemcitabine, S1 and immunotherapy against pancreatic cancer.pancreatic cancerJPRN-UMIN000027565Department of Gastroenterology and Hepatology, School of Medicine, Kochi University6